The collection require sponsors of any drug, biologic or device marketing application to certify to the absence of clinical investigators and/or disclose those financial interests as required, when covered clinical studies are submitted to FDA in support of product marketing.
The estimated number of respondents has increased from 902 to 1,000 for Certification, from 90 to 100 for Disclosure, and from 902 to 1,000 for Recordkeeping due to an increase in the estimated number of affected applications. The estimated number of respondents for third-party disclosure has decreased from 10,554 to 7,106. The sum of these adjustments has resulted in a 414-hour decrease of the total hour burden. No program changes were made.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.